Clinical Trials for Mesothelioma Patients: Immunotoxin Therapy Outcome Measures

Read about the outcome measures for a current clinical trial being conducted to study the effects of Immunotoxin Therapy for patients who have been diagnosed with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only. At this time, the study is currently being conducted only in Zurich, Switzerland.

Primary Outcome Measures:
• Maximum tolerated dose of SS1(dsFv)-PE38 immunotoxin [ Designated as safety issue: Yes ]
• Pharmacokinetics of SS1(dsFv)-PE38 immunotoxin [ Designated as safety issue: No ]
• Antitumor response [ Designated as safety issue: No ]

Secondary Outcome Measures:
• Measurement of antibody formation to drug and impact on pharmacokinetics [ Designated as safety issue: No ]

Recruitment Information:
Recruitment Status: Recruiting
Enrollment: 24
Estimated Start Date: June 2007
Estimated Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)

Courtesy of ClinicalTrials.gov, a service of the U.S. National Institutes of Health

Other helpful links:

Asbestos Asbestos
Asbestos and lung cancer Asbestos and lung cancer
Mesothelioma attorney Mesothelioma attorney
Mesothelioma Lawyer Mesothelioma lawyer
Asbestos attorney Asbestos attorney